News

Inflammatory rheumatic diseases raise venous thromboembolism risk


 

FROM ARTHRITIS RESEARCH & THERAPY

References

Individuals with inflammatory rheumatic diseases such as inflammatory arthritis, vasculitis, and connective tissue diseases, have a threefold increase in the risk of venous thromboembolism, compared with the general population, according to a meta-analysis.

The meta-analysis of 25 studies – 10 of which included patients with rheumatoid arthritis (RA) – found those with RA were more than twice as likely to develop deep vein thrombosis or a pulmonary embolism, compared with an age- and sex-matched individuals who had other comorbidities such as diabetes, peripheral vascular disease/coronary artery disease, and malignancy (OR, 2.23; 95% confidence interval, 2.02-2.47). The RA patients had a cumulative venous thromboembolism (VTE) incidence of 2.18% (Arthritis Res. Ther. 2014;16:435 [doi:10.1186/s13075-014-0435-y]).

Dr. Janet Pope

Dr. Janet Pope

Ten studies comprising 54,697 patients with systemic lupus erythematosus showed a cumulative thrombosis incidence of 7.29% (95% CI, 5.82%-8.75%). Other diseases for which the investigators calculated cumulative incidence rates of VTE, based on four studies apiece, were Sjögren’s syndrome (2.18%; 95% CI, 0.79%-3.57%), inflammatory myositis (4.03%; 95% CI, 2.38%-5.67%), Antineutrophil cytoplasmic antibody vasculitis (7.97%; 95% CI, 5.67%-10.28%), and systemic sclerosis (3.13%; 95% CI, 1.73%-4.52%).

“We believe that the increased VTE risk is associated with the activity of the inflammatory diseases, rather than with the treatments used for controlling the disease,” wrote Dr. Jason Lee of the University of Western Ontario, London, and Dr. Janet Pope, of the division of rheumatology at St. Joseph’s Health Care, London, Ont.

The authors said that they had no conflicts of interest.

Recommended Reading

Frozen or powdered? Anticoagulation options in trauma are expanding
MDedge Cardiology
Apixaban approved for treating DVT, pulmonary embolism and reducing risk of recurrence
MDedge Cardiology
Evidence questioned in debate over monitoring dabigatran levels to avert bleeds
MDedge Cardiology
Novel anticoagulants given to 60% of newly diagnosed AF patients
MDedge Cardiology
Blood test charges vary widely among California hospitals
MDedge Cardiology
Stroke risk skyrocketed after intracranial hemorrhage in warfarin users
MDedge Cardiology
NHLBI expert panel issues guideline on sickle cell disease
MDedge Cardiology
NHLBI expert panel issues guidelines on sickle cell disease
MDedge Cardiology
Most acute VTE therapies yield similar outcomes
MDedge Cardiology
New ischemic strokes temper panel’s enthusiasm for Watchman
MDedge Cardiology